A novel manganese glycerophosphate vaccine gel elicits broad and durable immunity across an aged and pox virus model
Year: 2026
Type: article
Abstract: T cells. Immunizing MnGp in 18-month-old mice elicited superior IgG and IgG1 antibody titers compared to Addavax, in addition to specific T cell responses in spleen and the draining lymph node. Finally, the co-immunization of MnGp and B5R (a vaccinia virus protein) induced higher B5R-specific antibody titers than Addavax and achieved full protection against the challenge with vaccinia virus. Overall, these findings corroborate the potential for MnGp gels as a novel vaccine platform.
Source: Nanoscale
DOI: 10.1039/d5nr03936c
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Funders: National Science Foundation, Foundation for the National Institutes of Health, North Carolina Biotechnology Center, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Directorate for Engineering, National Cancer Institute, National Institute of Allergy and Infectious Diseases, Division of Electrical, Communications and Cyber Systems, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
Awards: NNCI: North Carolina Research Triangle Nanotechnology Network (RTNN), G1676019983, G2075610922, G2317638881, G3275407028, G361606513, G4751247203, G4758380462, G5371541054, G5973914729, G6039814245, G6061660363, G6112818666, G6810723037, G6904994858, G7366156696, G7944007550, G7998276848, G9000033364, G9000101633, Cancer Center Support Grant, G958207224
OpenAlex ID: W7155014582